Braidwell LP Acquires New Holdings in Sarepta Therapeutics, Inc. $SRPT

Braidwell LP bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the 3rd quarter, HoldingsChannel reports. The institutional investor bought 832,100 shares of the biotechnology company’s stock, valued at approximately $16,035,000.

Other institutional investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its holdings in shares of Sarepta Therapeutics by 214.2% during the first quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company’s stock worth $344,000 after purchasing an additional 3,671 shares during the period. Great Lakes Advisors LLC acquired a new stake in Sarepta Therapeutics in the first quarter valued at $224,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Sarepta Therapeutics by 129.4% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,052 shares of the biotechnology company’s stock valued at $103,000 after purchasing an additional 3,414 shares during the period. PNC Financial Services Group Inc. raised its position in Sarepta Therapeutics by 61.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 3,779 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 1,444 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Sarepta Therapeutics by 3.0% during the 2nd quarter. Geode Capital Management LLC now owns 1,875,997 shares of the biotechnology company’s stock worth $32,085,000 after buying an additional 55,076 shares during the period. 86.68% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total transaction of $294,201.97. Following the transaction, the chief operating officer directly owned 193,300 shares in the company, valued at approximately $4,312,523. This represents a 6.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Stephen Mayo sold 7,239 shares of the firm’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $17.02, for a total transaction of $123,207.78. Following the sale, the director directly owned 1,765 shares of the company’s stock, valued at approximately $30,040.30. This trade represents a 80.40% decrease in their position. The SEC filing for this sale provides additional information. 7.60% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Stock Down 3.8%

Shares of NASDAQ:SRPT opened at $16.40 on Friday. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of -1.94, a P/E/G ratio of 0.24 and a beta of 0.42. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.32 and a quick ratio of 1.48. The business’s 50-day moving average is $19.43 and its 200-day moving average is $19.99. Sarepta Therapeutics, Inc. has a 1 year low of $10.41 and a 1 year high of $103.32.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing the consensus estimate of ($0.87) by ($2.71). The business had revenue of $442.93 million for the quarter, compared to the consensus estimate of $390.95 million. Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. The firm’s revenue for the quarter was down 32.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.90 EPS. Equities research analysts predict that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on SRPT. Wall Street Zen upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Mizuho lifted their price objective on Sarepta Therapeutics from $26.00 to $31.00 and gave the stock an “outperform” rating in a research note on Thursday. Wells Fargo & Company reduced their target price on Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a report on Friday, February 27th. Wedbush decreased their target price on shares of Sarepta Therapeutics from $34.00 to $29.00 and set an “outperform” rating for the company in a research report on Monday, March 2nd. Finally, Citigroup raised their price target on shares of Sarepta Therapeutics from $8.00 to $9.00 and gave the stock a “sell” rating in a report on Tuesday, March 10th. Nine investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $32.15.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.